相关实验视频

Updated: Mar 15, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

甲状腺垂体神经内分泌瘤:分子病理学,诊断挑战和受体向治疗策略

Kazunori Kageyama¹, Keisuke Sato¹, Mizuki Tasso¹

¹Division of Diabetes, Metabolism and Endocrinology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Sendai 983-8536, Japan.

|March 14, 2026

概括

甲状腺垂体神经内分泌瘤 (PitNETs) 是一种罕见的瘤,会导致中央甲状腺功能障碍. 索马托斯坦素受体连接体疗法为这些PIT1血统瘤提供了有效的管理.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
病理学病理学病理学

背景情况:

甲状腺增生性垂体神经内分泌瘤 (PitNETs) 是罕见的,自主分泌甲状腺刺激激素 (TSH),导致中央甲状腺功能障碍.
2022年世界卫生组织分类将它们定义为PIT1系PitNET,提高了病理学准确性.
这些宏腺瘤往往表现出侵入性生长,使手术切除复杂化,并需要多式治疗.

研究的目的:

审查有关瘤生物学和治疗甲状腺营养不良的PitNETs的当前见解.
讨论分类,受体分析和分子病理学的进展,以进行精细的诊断和个性化治疗.
探索受体向和分子信息化疗法的未来前景.

主要方法:

目前关于甲状腺营养不良的PitNETs的文献综述.
分析分子病理学,包括细胞循环控制,甲状腺激素反和生长因子信号.
评估免疫组织化学标记物,如PIT1,TSH和体静止素受体亚型 2.

主要成果:

甲状腺形PitNETs缺乏反复的驱动突变,但显示异质的分子变化.
索马托斯坦素受体亚型2的强烈表达为索马托斯坦素受体连接体治疗提供了理由.
索马托斯塔丁受体连接体对许多患者的激素控制和瘤稳定/收缩有效.

结论:

分类和分子理解的进步完善了对甲状腺养动物PitNETs的诊断策略.
索马托斯坦素受体连接体治疗是管理这些瘤的基石.
准确的区分与对甲状腺β激素的耐药性对于适当的管理至关重要.

关键词:

在PIT1中,PIT1是PIT1.这就是TSHomaoma.甲状腺功能过强症甲状腺功能过强症下垂体的神经内分泌瘤索马托斯坦因子受体是什么甲状腺增生动物甲状腺增生动物

更多相关视频

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...